Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Cardiff Oncology to Present at Upcoming Investor Conferences
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.